Literature DB >> 3578323

In vitro activity of ciprofloxacin against gram-positive cocci.

A L Barry, R N Jones.   

Abstract

In vitro studies compared the activities of ciprofloxacin, vancomycin, and fusidic acid against staphylococci, streptococci, and enterococci. Against 111 methicillin-resistant and 162 methicillin-susceptible staphylococcal strains, fusidic acid was the most potent of the three drugs (minimal inhibitory concentration [MIC] for 90 percent of the strains was 0.06 microgram/ml). Ciprofloxacin and vancomycin were also effective anti-staphylococcal drugs (MIC of ciprofloxacin for 90 percent of the strains was 0.5 microgram/ml and of vancomycin was 1.0 microgram/ml). Ciprofloxacin had a more rapid bactericidal effect against staphylococci than did vancomycin. Neither vancomycin nor ciprofloxacin alone had useful bactericidal activity against enterococci. Streptococci were only marginally susceptible to ciprofloxacin (MIC for 90 percent of the strains was 1.0 to 4.0 micrograms/ml for different species). Vancomycin was superior to ciprofloxacin in its anti-streptococcal activity (MIC for 90 percent of the strains was 0.25 to 0.5 microgram/ml). The promising in vitro anti-staphylococcal activity of ciprofloxacin deserves further consideration in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3578323

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  15 in total

1.  Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and temafloxacin.

Authors:  A L Barry; M A Pfaller; P C Fuchs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-03       Impact factor: 3.267

2.  Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin.

Authors:  E Pérez-Trallero; J M Garcia-Arenzana; J A Jimenez; A Peris
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-12       Impact factor: 3.267

3.  Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin.

Authors:  A L Barry; P C Fuchs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

Review 4.  Clinical importance and epidemiology of quinolone resistance.

Authors:  Eu Suk Kim; David C Hooper
Journal:  Infect Chemother       Date:  2014-12-29

5.  In vitro activity of ceftriaxone and other cephalosporins against 602 clinical isolates of staphylococci from geographically diverse medical centers.

Authors:  M A Pfaller; A L Barry; L D Sabath; B N Kreiswirth; P R Murray; P C Fuchs; J C McLaughlin
Journal:  Eur J Epidemiol       Date:  1993-11       Impact factor: 8.082

6.  Ciprofloxacin in general practice.

Authors:  P M Donaldson; A P Pallett; M P Carroll
Journal:  BMJ       Date:  1994-05-28

Review 7.  Fluoroquinolones: place in ocular therapy.

Authors:  A Smith; P M Pennefather; S B Kaye; C A Hart
Journal:  Drugs       Date:  2001       Impact factor: 9.546

8.  Spontaneous peritonitis caused by Enterococcus faecium.

Authors:  J Pascual; A Sureda; A Lopez-San Roman; R Barcena; L De Rafael; J Hernandez-Cabrero; D Boixeda
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

Review 9.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

10.  Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Committee on Antimicrobial Agents. Canadian Infectious Disease Society.

Authors:  T J Louie
Journal:  CMAJ       Date:  1994-03-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.